stocks logo

NRSN

Neurosense Therapeutics Ltd
$
2.030
0(0.000%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.030
Open
2.030
VWAP
2.00
Vol
225.85K
Mkt Cap
48.70M
Low
1.935
Amount
452.04K
EV/EBITDA(TTM)
--
Total Shares
18.04M
EV
45.32M
EV/OCF(TTM)
--
P/S(TTM)
--
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Show More
2 Analyst Rating
up Image
589.66% Upside
Wall Street analysts forecast NRSN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRSN is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
up Image
589.66% Upside
Current: 2.030
sliders
Low
14.00
Averages
14.00
High
14.00
D. Boral Capital
Jason Kolbert
Buy
initiated
$14
2025-05-12
Reason
Maxim Group
Naz Rahman
Strong Buy
to
Hold
Downgrades
n/a
2024-12-16
Reason

Valuation Metrics

The current forward P/E ratio for Neurosense Therapeutics Ltd (NRSN.O) is -4.46, compared to its 5-year average forward P/E of -1.89. For a more detailed relative valuation and DCF analysis to assess Neurosense Therapeutics Ltd 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.89
Current PE
-4.46
Overvalued PE
-1.09
Undervalued PE
-2.68

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
FY2024Q4
YoY :
-100.00%
N/A
Operating Profit
FY2024Q4
YoY :
-100.00%
N/A
Net Income after Tax
FY2024Q4
YoY :
-100.00%
N/A
EPS - Diluted

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

NRSN News & Events

Events Timeline

2025-01-06 (ET)
2025-01-06
08:06:45
NeuroSense regains Nasdaq compliance
select
2024-12-23 (ET)
2024-12-23
08:02:25
NeuroSense enters binding term sheet to advance PrimeC for ALS
select
2024-12-06 (ET)
2024-12-06
15:34:27
NeuroSense files to sell 6.6M ordinary shares for holders
select
Sign Up For More Events

News

9.0
05-12Benzinga
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights
4.0
05-12Benzinga
This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday
5.0
05-07PRnewswire
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
Sign Up For More News

FAQ

arrow icon

What is Neurosense Therapeutics Ltd (NRSN) stock price today?

The current price of NRSN is 2.03 USD — it has increased 0 % in the last trading day.

arrow icon

What is Neurosense Therapeutics Ltd (NRSN)'s business?

arrow icon

What is the price predicton of NRSN Stock?

arrow icon

What is Neurosense Therapeutics Ltd (NRSN)'s revenue for the last quarter?

arrow icon

What is Neurosense Therapeutics Ltd (NRSN)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Neurosense Therapeutics Ltd (NRSN)'s fundamentals?

arrow icon

How many employees does Neurosense Therapeutics Ltd (NRSN). have?

arrow icon

What is Neurosense Therapeutics Ltd (NRSN) market cap?